Author: Dálifer Freites Núñez
Wang et al. (OP0274) aimed to establish a pharmacodynamic model-based meta-analysis to quantitatively evaluate placebo response to intra-articular injections in OA clinical trials and to identify the influencing factors. This study developed a pharmacodynamic model that could quantitatively describe the placebo response of intra-articular injections for OA across various subpopulations and trial variables. These findings could serve as a useful reference for current clinical practices and future clinical trial design.
Yazici et al. (OP0326) evaluated the efficacy and safety of long-term, repeated usage of Lorecivivint (LOR) in patients with severe knee OA. In this advanced knee OA cohort, LOR 0.07 mg appeared safe and OA-07 met its primary objective with repeat LOR injections showing medial JSW improvement compared to PBO after 3 years (3 injections). Beneficial LOR effects compared to PBO were also seen across pain and function PROs and were more pronounced in KL2 patients. PBO patients who crossed to LOR treatment showed similar benefits after 12 months, providing further evidence of potential efficacy. LOR continues to show promise as a safe, disease-modifying knee OA treatment.
Martin et al. (POS0319) aimed to provide a screening of male osteoporosis (OP) in a random population of aging men to provide real-life data on the actual fracture risk in aging men who wouldn’t be otherwise evaluated on the basis of clinical guidelines. Based on clinical experience, published guidelines and epidemiology of secondary causes and risk factors for OP in men, we suggest that OP should be considered in all men when risk factors for low BMD and fractures are present, independently from age. Age per se is sufficient for screening after the age of 60 years.
Oliveira et al. (OP0080) reported from the EudraVigilance database that zoledronate treatment demonstrated a higher incidence of jaw osteonecrosis, while denosumab represented the safest drug for this adverse event. However, indication for the use of zoledronate was mostly in an oncologic context.
Naranjo et al. (OP0063) aimed to analyze the prophylaxis habits of glucorticosteroid-induced OP (GIOP). OP prophylaxis in patients who receive high doses of GC was associated with concurrent rheumatic or neurological disease and being a woman over 70 years with a bone densitometry. However, in the whole studied population, only 1 in 7 patients received OP prophylaxis.
ABOUT THE AUTHOR
Dálifer Freites Núñez
Dalifer is a Rheumatologist at Hospital Clínico San Carlos, Madrid – Spain.
Dálifer is a member of the Social Media Sub-committee with a genuine interest and enthusiasm in research on Immune-mediated inflammatory diseases and their treatments.